EUVIMEDEUVIMED entdecken
Crossref

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study

Shen Zhao, Kehui Chen, Xinyi Shi, Jing Sun, Wenfeng Fang, Yan Huang, Li Zhang

Clinical Lung Cancer · 2023

DOI: 10.1016/j.cllc.2023.06.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von Shen Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen Uni…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Pfizer Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is still a substantial need of more treatment options for patients with limited-stage small cell lung cancer (LS-SCLC). The standard therapy for LS-SCLC is platinum-based doublet chemotherapy administered concurrently with thoracic radiotherapy (cCRT). In China, sequential chemoradiotherapy (sCRT) is also a common practice. However, the disease inevitably progresses in most patients despite the curative intent and initial response. MATERIALS AND METHODS: Sugemalimab is an anti-programmed death ligand-1 (PD-L1) antibody that improved clinical outcomes for patients with stage III non-small cell lung cancer after cCRT or sCRT. The SUPPASS study is a phase II/III, randomized, double-blind, placebo-controlled, multicenter study (NCT05623267) that aims to investigate the efficacy and tolerability of sugemalimab as consolidation therapy in patients with LS-SCLC who have no progression following cCRT or sCRT. Approximately 346 patients will be randomized in a 1:1 ratio to receive sugemalimab 1200 mg or placebo every 3 weeks for up to 12 months. The primary endpoint is progression-free survival (PFS). Key secondary endpoints include overall survival (OS), landmark PFS rate, landmark OS rate, objective response rate and safety. Longitudinal molecular residual disease (MRD) testing will be performed as preplanned exploratory analysis. CONCLUSION: Study results will help demonstrate the efficacy and tolerability of anti-PD-L1 antibody consolidation therapy in LS-SCLC patients who have not progressed following cCRT or sCRT, and help determine the clinical implications of MRD in LS-SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaHumansAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyConsolidation ChemotherapyDouble-Blind MethodClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Clinical trialConsolidation therapyLS-SCLCMolecular residual diseaseProgrammed cell death ligand-1 (PD-L1)

Substanzen

sugemalimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Shanghai Zhengu Biological Technology Co., Ltd. Shanghai, China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: huangyan@…
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: zhangli@s…

Förderung

  • Pfizer Pharmaceuticals

Zitieren

APA

Zhao, S., Chen, K., Shi, X., Sun, J., Fang, W., Huang, Y., & Zhang, L. (2023). Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.06.009

Vancouver

Zhao S, Chen K, Shi X, Sun J, Fang W, Huang Y, et al. Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.06.009

BibTeX
@article{Zhao2023,
  author = {Zhao, Shen and Chen, Kehui and Shi, Xinyi and Sun, Jing and Fang, Wenfeng and Huang, Yan and Zhang, Li},
  title = {Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study},
  journal = {Clinical Lung Cancer},
  year = {2023},
  doi = {10.1016/j.cllc.2023.06.009}
}
Kostenlos starten →